Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Cancer · HLA-A*02:01-positive
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 600 (planned)
- Started
- Jan 10, 2024
- Main results expected
- Nov 30, 2026
- Fully finished
- Nov 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)
Measured over: Up to ~24 months
Dose Escalation: Percentage of participants with ≥1 adverse event (AE)
Measured over: Up to ~24 months
Dose Escalation: Percentage of participants with ≥1 serious adverse event (SAE)
Measured over: Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in electrocardiogram (ECG) recordings
Measured over: Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in vital signs
Measured over: Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in laboratory results
Measured over: Up to ~24 months
Dose Escalation: Percentage of participants with a dose interruption, reduction, or discontinuation
Measured over: Up to ~24 months
Expansion: Best Overall Response (BOR) as Determined by RECIST v1.1
Measured over: Up to ~24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06840119 · record last updated 2026-01-28 · checked 2026-11-09 15:47 UTC